Welcome to the official InxMed website

CN EN

LOGO

学术文献

学术文献

首页
>
发表文献
A phase Ib study of IN10018 in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum-resistant ovarian cancer.
A phase Ib study of IN10018 in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum-resistant ovarian cancer.
○  A phase Ib study of IN10018 in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum-resistant ovarian cancer.
发布时间 2022-06-07
查看详情
Focal adhesion kinase inhibitors, a heavy punch to cancer
Focal adhesion kinase inhibitors, a heavy punch to cancer
○  Focal adhesion kinase inhibitors, a heavy punch to cancer
发布时间 2021-11-25
查看详情
Inhibition of focal adhesion kinase enhances antitumor response of radiation therapy in pancreatic cancer through CD8+ T cells
Inhibition of focal adhesion kinase enhances antitumor response of radiation therapy in pancreatic cancer through CD8+ T cells
○  Inhibition of focal adhesion kinase enhances antitumor response of radiation therapy in pancreatic cancer through CD8+ T cells
发布时间 2021-08-08
查看详情
Focal Adhesion Kinase (FAK) Inhibition Synergizes with KRAS G12C Inhibitors in Treating Cancer through the Regulation of the FAK–YAP Signaling
Focal Adhesion Kinase (FAK) Inhibition Synergizes with KRAS G12C Inhibitors in Treating Cancer through the Regulation of the FAK–YAP Signaling
○  Focal Adhesion Kinase (FAK) Inhibition Synergizes with KRAS G12C Inhibitors in Treating Cancer through the Regulation of the FAK–YAP Signaling
发布时间 2021-02-15
查看详情
上一页
1
office@inxmed.com
+86-10-85887500
+86-592-6537605
upspower1999
img
InxMed

我们致力于开发针对肿瘤耐药和转移的创新疗法

快速链接

关于应世 研发策略 新药管线 全球合作 新闻动态 加入应世

联系我们

电话： 025-58251030
邮箱： office@inxmed.com
公司地址： 南京市江北新区探秘路73号树屋十六栋D-2栋3层

在线留言

关注我们：

img img

CopyRight © 2022 应世生物 All Rights Reserved.

京ICP备19001572号-1
网站建设： 中企动力 苏州